We are excited to announce that Mabtech, a leading Swedish biotech company renowned for developing innovative immunoassays for life science research, has successfully raised an impressive $5 million in funding. This significant investment will play a crucial role in propelling our mission of equipping the scientific community with cutting-edge tools, particularly in the realms of ELISpot, FluoroSpot, and ELISA technologies. Since our inception in Stockholm in 1986, we have dedicated ourselves to creating a comprehensive range of high-quality monoclonal antibodies, kits, peptide pools, and instruments designed for in vitro applications. The funds will allow us to further enhance our research and production capabilities, ultimately driving advancements in biotechnology and healthcare. Nestled in Nacka Strand, just east of Stockholm's inner city, all our operations, from finance and IT to quality control and sales, are run from our headquarters, ensuring that every product released into the market meets our stringent quality standards. Moreover, with a sales office located in Cincinnati, Ohio, and robust collaborations with distributors worldwide, we are committed to expanding our global reach. At Mabtech, we believe that quality is more than just a word; it is a mindset that permeates every initiative we undertake. As we embark on this new chapter fueled by our funding success, we invite members of the scientific community to engage with us. Together, we can foster collaboration that drives scientific progress and breakthroughs. Thank you for being a part of our journey towards advancing life science research!








